Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer

As the cost of health care rises globally, there is a pressing need to recognize that ever-escalating treatment costs must be matched by improved outcomes; resources spent on care that delivers no benefit may deprive others of beneficial care. As such, we welcome the manuscript by Parikh et  al,1 who seek to estimate the cost-effectiveness of stereotactic radiation therapy for oligometastatic prostate cancer.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research